title: Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost.
abstract: OBJECTIVE
  The aim of this study was to study long-term intraocular pressure (IOP) lowering following a switch to bimatoprost in patients with open-angle glaucoma (OAG) not at target IOP while on latanoprost either as monotherapy or as polytherapy with other topical adjunctive agents.
  
  
  METHODS
  A retrospective review of OAG patients, with <20% IOP lowering from pretreatment baseline while on latanoprost either as monotherapy or in combination with adjunctive agents who were switched to bimatoprost, was conducted. Main outcome measures were mean IOP at 6, 12, and 24 months following the switch to bimatoprost and percent IOP lowering from baseline IOP before the switch.
  
  
  RESULTS
  Records of 30 patients (30 right eyes [OD], 29 left eyes [OS]) were reviewed. Mean IOP preswitch was 23.1 +/- 4.3 mmHg in OD and 22.3 +/- 3.8 mmHg in OS. Postswitch to bimatoprost, IOP was significantly reduced (P < 0.005) at each of the time points studied and patients experienced additional IOP lowering ranging from 17.8 to 22.0% in OD and 15.0-24.0% in OS. Bimatoprost was well tolerated in all but 1 patient.
  
  
  CONCLUSIONS
  Significant additional long-term IOP lowering may be achieved by switching to bimatoprost in patients with open-angle glaucoma who are not at target IOP with latanoprost.
authors.affiliation: Department of Ophthalmology, University of Illinois at Chicago, Chicago, IL, USA. ssonty@msn.com
authors.forename: Sriram
authors.initials: S
authors.lastname: Sonty
authors.forename: Vikrant
authors.initials: V
authors.lastname: Donthamsetti
authors.forename: Gautam
authors.initials: G
authors.lastname: Vangipuram
authors.forename: Afzal
authors.initials: A
authors.lastname: Ahmad
mesh_terms: D000368:Aged; D000577:Amides / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D009883:Ophthalmic Solutions; D010865:Pilot Projects; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost